CTLA4 and diabetes mellitus: In the analysis of Kotwal et al., which involved 1444 patients treated with ICI (anti-CTLA4, anti-PD-1, anti-PD-L1), new onset diabetes was found in 0.8% of patients, and 0.6% experienced a worsening of pre-existing diabetes.